A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild‐to‐moderate ulcerative colitis - Danese - 2019 - United European Gastroenterology Journal - Wiley Online Library
Remission endpoints in ulcerative colitis: A systematic review
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study | Gut
Comparison of the Ulcerative Colitis Disease Activity Index between the... | Download Table
Inflammatory Bowel Disease | Clinical Gate
Identification of useful genes from multiple microarrays for ulcerative colitis diagnosis based on machine learning methods | Scientific Reports
Cells | Free Full-Text | A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis
Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study
Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set - Clinical Gastroenterology and Hepatology
New approaches in the follow-up of patients suffering from inflammatory bowel diseases
Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study | BMJ Open Gastroenterology
A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis
Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis - ScienceDirect
Inflammatory Bowel Disease-Associated Interleukin-33 Is Preferentially Expressed in Ulceration-Associated Myofibroblasts - The American Journal of Pathology
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions - Clinical Gastroenterology and Hepatology
Cochrane
UC-Disease Activity Index | Download Table
The Efficacy of the Consumption of n-3 Polyunsaturated Fatty Acids for the Maintenance of Remission in Patients with Inflammatory Bowel Disease
Guidelines for the management of ulcerative colitis in the adult population (update)
CDAI calculator (Crohn's Disease Activity Index)
WO2014096873A1 - Biomarkers in inflammatory bowel disease - Google Patents
Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis - Ma - 2018 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Epidermal Growth Factor Enemas with Oral Mesalamine for Mild-to-Moderate Left-Sided Ulcerative Colitis or Proctitis | NEJM
![PDF] Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3487ab107b3dfb52cb7dc2f7872fa75c27538395/5-Table4-1.png "PDF] Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis | Semantic Scholar")